Skip to main content

Table 1 Parameters at baseline and at the 8 weeks follow-up

From: Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

 

Control

Diabetes

Diabetes+dapa

Baseline

 Body weight, kg

3.3 ± 0.1

3.3 ± 0.1

3.4 ± 0.1

 Total cholesterol (mg/dL)

29.8 ± 3.1

32.3 ± 4.1

27.9 ± 2.5

 Triglyceride (mg/dL)

42.3 ± 5.9

38.2 ± 4.6

36.9 ± 5.9

 High-density lipoprotein (mg/dL)

13.9 ± 2.2

14.8 ± 2.5

12.9 ± 1.9

 Low-density lipoprotein (mg/dL)

7.4 ± 1.5

9.9 ± 3.0

7.6 ± 1.1

 FBG (mg/dL)

133 ± 8

427 ± 36***

441 ± 38***

At 8 week follow-up

 Body weight, kg

3.6 ± 0.1

3.5 ± 0.2

3.8 ± 0.1

 Total cholesterol (mg/dL)

268 ± 42

645 ± 34***

266 ± 27†††

 Triglyceride (mg/dL)

91.4 ± 32.6

669 ± 161***

138 ± 35††

 High-density lipoprotein (mg/dL)

40.6 ± 2.5

26.1 ± 2.4***

25.7 ± 2.9***

 Low-density lipoprotein (mg/dL)

209 ± 36

486 ± 34***

213 ± 21†††

 FBG (mg/dL)

136 ± 4

445 ± 48***

251 ± 36*,†

  1. Values are means ± SEM (n = 10 per group)
  2. FBG fasting blood glucose
  3. *p < 0.05, ***p < 0.001 compared to control group, p < 0.05, ††p < 0.01, †††p < 0.001 compared to diabetes group